Recent events
Recent events tied to this brand in public sources.
Back to profile81 entries · Page 4 of 5
2020
IDEAYA and Pfizer expanded clinical trial collaboration and supply agreement
IDEAYA announced that it had expanded its clinical trial collaboration and supply agreement with Pfizer for an IDEAYA-sponsored combination study of IDE196 and crizotinib. IDEAYA will sponsor the study and Pfizer will supply crizotinib.
2020
Bridgewest subsidiary acquires Pfizer’s Adelaide manufacturing facility
The Bridgewest Group announced that a subsidiary acquired Pfizer’s biologics manufacturing facility in Adelaide, Australia. Pfizer affiliate Hospira Adelaide Pty Ltd. is to continue operating the facility under a sale-and-leaseback arrangement until the third quarter of 2021, when Bridgewest is to assume full responsibility for the facility and staff.
2020
Bridgewest announces purchase of Pfizer's Adelaide manufacturing facility
The Bridgewest Group announced that its subsidiary had purchased Pfizer's biologics manufacturing facility in Adelaide, Australia. Hospira Adelaide Pty Ltd., an affiliate of Pfizer Inc., was to continue operating it under a leaseback arrangement until Q3 2021, when Bridgewest would assume full operational responsibility.
2020
Pfizer and CanSino vaccine collaboration
Pfizer and CanSino are collaborating, with Pfizer's vaccine promotion team joining the collaboration.
2020
FDA approves BAVENCIO for first-line maintenance treatment
The US FDA approved the supplemental Biologics License Application for BAVENCIO for maintenance treatment of certain patients with locally advanced or metastatic urothelial carcinoma whose disease had not progressed with first-line platinum-containing chemotherapy.
2020
FDA approves Pfizer's NYVEPRIA biosimilar
The U.S. Food and Drug Administration approved Pfizer's NYVEPRIA, a biosimilar to Neulasta. It is approved to help reduce the chance of infection due to low white blood cell counts in certain people with non-myeloid cancer receiving anti-cancer medicines.
2020
ICE announces public-private partnership to combat counterfeit PPE
U.S. Immigration and Customs Enforcement announced a partnership with companies including 3M, Amazon, Merck, Pfizer, Citi and Alibaba to help stop counterfeit face masks, coronavirus tests and other PPE and medical supplies from entering the U.S. market.
2020
Companies partner with ICE on counterfeit-goods effort
3M, Amazon, Pfizer and other companies are working with U.S. Immigration and Customs Enforcement to identify suspicious shipments and take down suspect online listings for counterfeit masks, coronavirus tests and other equipment.
2020
AMRA Medical and Pfizer expanded their research collaboration
AMRA Medical announced that it expanded its collaboration with Pfizer to investigate body fat distribution and muscle composition across diseases and metabolic health. The renewed partnership involves analysis of body composition data from 100,000 UK Biobank participants.
2020
FDA approves Pfizer’s Braftovi combination for metastatic colorectal cancer
The US Food and Drug Administration approved Pfizer’s Braftovi plus cetuximab to treat BRAFV600E-mutant metastatic colorectal cancer after prior therapy.
2020
Pfizer responds to controversy over China’s exclusion from vaccine collaboration
Pfizer said its collaboration with BioNTech did not include China because BioNTech had already partnered with Fosun Pharma for the Chinese market. Pfizer said it was working to resolve details and was committed to access to medicines and vaccines for patients in China and globally.
2020
Pfizer and Insilico Medicine enter research collaboration
Pfizer entered a research collaboration with Insilico Medicine to use Insilico’s technology to identify real-world evidence for drug targets in multiple therapeutic areas.
2019
Pfizer selects a second target in collaboration with BioInvent
BioInvent announced that Pfizer selected a second target under their cancer immunotherapy research collaboration and license agreement, triggering a $300,000 payment from Pfizer to BioInvent.
2019
FDA approves Xtandi for metastatic castration-sensitive prostate cancer
The FDA approved Xtandi (enzalutamide) for treating patients with metastatic castration-sensitive prostate cancer.
2019
NCCN announces funded metastatic breast cancer projects with Pfizer support
NCCN announced proposals selected to receive funding in collaboration with Pfizer Global Medical Grants. Up to $1.4 million will be provided by NCCN through a Pfizer grant over three years to support projects focused on improving care and outcomes for people with metastatic breast cancer.
2019
FDA approves Pfizer’s ABRILADA
The U.S. Food and Drug Administration approved ABRILADA, Pfizer’s biosimilar to Humira, for treatment of certain patients with the inflammatory conditions listed in the announcement. Pfizer said it was working to make the product available in the United States and its current plans were to launch it in 2023.
2019
CENTOGENE and Pfizer sign data-access and collaboration agreement
CENTOGENE announced a data-access and collaboration agreement with Pfizer. The agreement gives Pfizer access to CENTOGENE's data repository for potential discovery and validation of genetic and biochemical targets related to rare-disease therapies; the companies also plan to mine the repository and jointly agree on any collaborative research projects.
2019
Pfizer raises its 2019 earnings forecast
Pfizer raised its earnings forecast for the year after reporting a higher-than-expected third-quarter profit, citing increased sales of Ibrance and a strong launch of Vyndaqel.
2019
Fitbit, Bristol Myers Squibb and Pfizer announce AFib detection collaboration
Bristol Myers Squibb and Pfizer, operating as the BMS-Pfizer Alliance, and Fitbit said they would collaborate to improve earlier detection of atrial fibrillation. They planned to create AFib detection software for Fitbit devices and submit it to the Food and Drug Administration.
2019
Pfizer launches counterfeit medicines awareness campaign
Pfizer announced the launch of a UK-wide campaign aimed at students to raise awareness of the risks of buying counterfeit medicines online. The campaign was set to run on Facebook and Instagram.